«The SGLT2 inhibitors, including empagliflozin, may be associated with osmotic diuresis and possible intravascular volume contraction, potentially predisposing patients to acute kidney injury, especially in individuals with impaired renal function, heart failure, elderly patients, or patients receiving loop diuretics, ACEIs, angiotensin receptor blockers (ARBs), and non-steroidal anti-inflammatory drugs (NSAIDs). The gene discussed is SLC5A2; the disease is heart failure.